Home > Insider Trading > Filing (0000921895-21-002138)

Filing Details

Accession Number:: 0000921895-21-002138
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-08-17 18:07:15
Reporting Period:: 2021-08-13

Accepted Time:: 2021-08-17 18:07:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
727510	Enzon Pharmaceuticals Inc.	ENZN	Biological Products, (No Disgnostic Substances) (2836)	222372868

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1265094	Jonathan Couchman	600 Fifth Avenue 2Nd Floor New York NY 10020	No	No	Yes	No
1459450	Myrexis, Inc.	600 Fifth Avenue 2Nd Floor New York NY 10020	No	No	Yes	No
1571659	Xstelos Corp.	600 Fifth Avenue 2Nd Floor New York NY 10020	No	No	Yes	No
1737322	Fund Family Couchman	600 Fifth Avenue 2Nd Floor New York NY 10020	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.01 Par Value	Disposition	2021-08-13	50,000	$0.39	350,000	No	4	S	Indirect	By Couchman Family Fund
Common Stock, $0.01 Par Value	Disposition	2021-08-13	57,500	$0.39	2,043,024	No	4	S	Indirect	By Xstelos Corp.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Couchman Family Fund
No	4	S	Indirect	By Xstelos Corp.

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, $0.01 Par Value	4,717,666	Indirect	By Jonathan Couchman
Common Stock, $0.01 Par Value	633,264	Indirect	By Myrexis, Inc.

Footnotes

This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation"), Xstelos Corp. ("Xstelos") and Myrexis, Inc. ("Myrexis") (collectively, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
Represents shares owned directly by Mr. Couchman. As the sole trustee of the Foundation, Mr. Couchman may be deemed to beneficially own the Shares owned by the Foundation. As the Chief Executive Officer of Xstelos, Mr. Couchman may be deemed to beneficially own the shares of Common Stock owned by Xstelos. As the Chief Executive Officer of Myrexis, Mr. Couchman may be deemed to beneficially own Shares of Common Stock owned by Myrexis.
Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.
Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
Represents Shares owned directly by Myrexis. Mr. Couchman is Chief Executive Officer of Myrexis. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Myrexis. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions and the reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commision, upon request, full information regarding the number of shares purchased at each separate price.